[{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fimaporfin","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"PCI Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PCI Biotech \/ Inapplicable"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"MDimune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PCI Biotech \/ MDimune","highestDevelopmentStatusID":"4","companyTruncated":"PCI Biotech \/ MDimune"},{"orgOrder":0,"company":"PCI Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"PCI Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"PCI Biotech \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"PCI Biotech \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by PCI Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : This collaboration is an additional mark of interest from a cutting-edge biotech company developing therapies with emerging advanced technologies, with a large potential in future medicine

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 01, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : MDimune

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : PCI of gemcitabine with Amphinex shows an innovative treatment that could potentially produce significant local tumour response in patients. The study is well designed to demonstrate the potential benefit of Amphinex induced PCI of gemcitabine in bile du...

                          Product Name : Amphinex

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          January 24, 2022

                          Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The interaction with the FDA and EMA initiated to explore the opportunity for a modified study design to address the retention risk in the control arm of the RELEASE study of Amphinex (Fimaporfin).

                          Product Name : Amphinex

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          July 12, 2021

                          Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The fimaChem treatment regimen consists of an intravenous injection of fimaporfin, a photosensitiser drug followed four days later by an intravenous infusion of gemcitabine and a laser light application in the bile duct.

                          Product Name : Amphinex

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          May 28, 2021

                          Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : First US patient has been enrolled into the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients.

                          Product Name : Amphinex

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          April 30, 2021

                          Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The European patent covers the intended use of fimaChem in combination with gemcitabine for the treatment of cholangiocarcinoma (bile duct cancer).

                          Product Name : Amphinex

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          November 16, 2020

                          Lead Product(s) : Fimaporfin,Cisplatin,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : Company's decision not to enter into a definitive agreement is primarily based on a strategic evaluation of current development needs. Results have continued to be achieved with the fimaNAc platform in the collaboration.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 21, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : PCI Biotech has announced case report series from the Phase I study with PCI Biotech's proprietary drug fimaporfin (AmphinexTM), for the treatment of inoperable extrahepatic bile duct cancer (eCCA), is accepted for publishing in Endoscopy International O...

                          Product Name : Amphinex

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          August 19, 2020

                          Lead Product(s) : Fimaporfin,Gemcitabine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank